The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides
Open accessAbstract
The inheritance of the apolipoprotein E (apoE) ϵ4 allele is a prevailing risk factor for sporadic and familial Alzheimer's disease (AD). ApoE isoforms bind directly to Alzheimer's amyloid β (Aβ) peptides both in vitro and in vivo. Recent studies suggest that association of apoE with lipids may modulate its interaction with Aβ. We examined the binding of lipid-associated and delipidated apoE3 and apoE4 isoforms to Aβ utilizing a solid-phase binding assay and estimated the dissociation constants for the interaction of various apoE and Aβ species. Using native apoE isoforms from stably transfected RAW 264 and human embryonic kidney 293 cells, apoE3 had greater affinity than apoE4 for both Aβ1-40 and Aβ1-42. Delipidation of apoE decreased its affinity for Aβ peptides by 5-10-fold and abolished the isoform-specificity. Conversely, incorporation of apoE isoforms produced by baculovirus-infected Sf9 cells into reconstituted human high-density-lipoprotein lipoparticles restored the affinity values for Aβ peptides and resulted in preferential binding of apoE3. The data demonstrate that native lipid-associated apoE3 binds to Aβ peptides with 2-3-fold higher affinity than lipid-associated apoE4. Since the isoforms' binding efficiency correlate inversely with the risk of developing late-onset AD, the results suggest a possible involvement of apoE3 in the clearance or routing out of Aβ from the central nervous system as one of the mechanisms underlying the pathology of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased levels of ApoE and lipidation of ApoE increase the intra-and extracellular microglial degradation of Ab 1 -42 by increasing the interaction between ApoE and Ab 1 -42 (15).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several in vitro studies have demonstrated that lipidated apoE2 and apoE3 bind Aβ with greater affinity compared to apoE4 (39, 51-54).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies demonstrate that the efficiency of complex formation between lipidated apoE and Aβ follows the order of apoE2 > apoE3 ≫ apoE4 (Tokuda et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Tokuda et al., 2000
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“studies have demonstrated that apoE4 does not clear plaques or soluble Aβ as well as apoE3 [45, 46].”
From Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation (2023) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High-affinity in vitro binding of A b to a 2M and to lipidated apoE3 and apoE4, and a lower-affinity binding to delipidated apoE isoforms has been well documented (23, 70).”
From Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier (2000) · cites this paper as [70]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107
Research works printed but not linked: 1
- Rebeck, G. W. and Hyman. B. T. (1999) Lipoprotein receptors in brain. In Clusterin in Normal Brain Functions and during Neurodegeneration (Finch, C. E., ed.), pp. 49-59, R. G. Landes Co., Austin 45
Cited by
Sorted by citations
Items 201–272 of 272
Crouchet, É., Lefèvre, M., Verrier, E. R., Oudot, M. A., Baumert, T. F., & Schuster, C. (2016) · Gut · doi:10.1136/gutjnl-2015-311289 · Cited by 12
Chen, X., Wang, B., Sarkar, A., Huang, Z., Ruiz, N. V., Yeung, A. T., Chen, R., & Han, C. (2025) · Science Advances · doi:10.1126/sciadv.adr5448 · Cited by 11
Regulation of Alzheimer's disease-associated proteins during epileptogenesis
von Rüden, E., Zellinger, C., Gedon, J., Walker, A., Bierling, V., Deeg, C. A., Hauck, S. M., & Potschka, H. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.08.037 · Cited by 11
Profiling of circulating chromosome 21‐encoded microRNAs , miR ‐155, and let‐7c, in down syndrome
Peréz-Villarreal, J. M., Aviña‐Padilla, K., Beltrán‐López, E., Guadrón‐Llanos, A. M., López‐Bayghen, E., Magaña‐Gómez, J. A., Meraz‐Ríos, M. A., Varela‐Echavarría, A., & Angulo‐Rojo, C. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1938 · Cited by 11
Effects of Alzheimer’s Disease-Related Proteins on the Chirality of Brain Endothelial Cells
Zhang, H., Fan, J., Zhao, Z., Wang, C., & Wan, L. Q. (2021) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-021-00669-w · Cited by 11
Effects of DHA (omega-3 fatty acid) and estradiol on amyloid β-peptide regulation in the brain
Majou, D., & Dermenghem, A.-L. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148681 · Cited by 10
Apolipoprotein E receptor pathways in Alzheimer disease
Schmidt, V., Carlo, A.-S., & Willnow, T. E. (2014) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1262 · Cited by 10
Monitoring the amyloid beta-peptide in vivo – caveat emptor
Thompson, P. W., & Lockhart, A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.004 · Cited by 10
Parkinson's disease: a long and difficult journey.
Casey, G. (2013) · PubMed · Cited by 10
Cao, Q., Sun, D., Tu, C., Wang, J., Fu, R., Gong, R., Xiao, Y., Liu, Q., & Li, X. (2025) · Communications Biology · doi:10.1038/s42003-025-07512-2 · Cited by 10
Abedin, M. J., & Kastanenka, K. V. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251411561 · Cited by 9
Mallick, S., Marshall, P. A., Wagner, C. E., Heck, M. C., Sabir, Z. L., Sabir, M. S., Dussik, C. M., Grozić, A., Kaneko, I., & Jurutka, P. W. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00707 · Cited by 8
Grenon, M. B., Papavergi, M.-T., Bathini, P., Sadowski, M. J., & Lemere, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115754 · Cited by 7
Alzheimer's Disease; Mechanism, Mutations, and Applications of Nano-Medicine
Maisam, M., Khan, M. T., Lodhi, M. S., Mou, K., Liu, Z., & Wei, D. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810258 · Cited by 7
Song, H., Ma, X., Xu, J., Song, Q., Meng, H., Gu, X. Q., Zhang, Q., Hou, L., Chen, L., Huang, Y., et al. (2018) · Nano Research · doi:10.1007/s12274-018-2107-8 · Cited by 7
Sarlak, Z., Moazzami, M., Hosseini, S. R. A., & Gharakhanlou, R. (2019) · PubMed · doi:10.22038/ijbms.2018.32911.7860 · Cited by 7
An insight into Alzheimer’s disease and its on-setting novel genes
Vigneswaran, J., Muthukumar, S. A., Shafras, M., & Pant, G. (2021) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-021-00420-2 · Cited by 7
Nedelkov, D., Tsokolas, Z. E., Rodrigues, M. S., Sible, I. J., Han, S. D., Kerman, B. E., Renteln, M., Mack, W. J., Pascoal, T. A., Yassine, H. N., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01795-7 · Cited by 6
Martins, I. J., Gupta, V. B., Wilson, A. C., Fuller, S. J., & Martins, R. N. (2014) · Current Proteomics · doi:10.2174/157016461103140922163729 · Cited by 7
Generation of novel anti‐apo E monoclonal antibodies that selectively recognize apo E isoforms
Ohgita, T., Sakai, K., Fukui, N., Namba, N., Nakano, M., Kiguchi, Y., Morita, I., Oyama, H., Yamaki, K., Nagao, K., et al. (2024) · FEBS Letters · doi:10.1002/1873-3468.14858 · Cited by 5
Patil, S. P., & Kuehn, B. R. (2024) · Pharmaceuticals · doi:10.3390/ph17040491 · Cited by 6
β-hexachlorocyclohexane as a Risk for Alzheimer’s Disease: A Pilot Study in North Indian Population
Chhillar, N., Singh, N., Banerjee, B., Bala, K., Sharma, D., Mustafa, M., & Mitrabasu (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.7726/ajad.2013.1004-1 · Cited by 5
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 5
AlQot, H. E., & Rylett, R. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-78751-2 · Cited by 5
The Impact of Apolipoprotein E Allelic Variants on Alzheimer’s Disease
Serrano, E., Sanz, P. G., & Barrantes, F. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_29 · Cited by 4
Patil, S. P., DiFlumeri, J., Wellington, J., Fattakhova, E., & Oravic, M. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110865 · Cited by 3
Abramova, O. V., Soloveva, K., Zorkina, Y., Gryadunov, D. A., Ikonnikova, A. Y., Fedoseeva, E., Emelyanova, M., Ochneva, A., Andriushchenko, N., Ka, P., et al. (2022) · Genes · doi:10.3390/genes13112174 · Cited by 3
Apolipoproteins in Different Amyloidoses
Sadowski, M., & Wısnıewskı, T. (2007) · Springer eBooks · doi:10.1007/0-387-25919-8_6 · Cited by 3
Electrochemical Detection of Isoform‐Specific Interaction between Apolipoprotein E and Amyloid‐β
Su, H., Jin, Y., Noroozifar, M., & Kerman, K. (2018) · ChemElectroChem · doi:10.1002/celc.201800985 · Cited by 3
Amyloid‐beta (1–40) peptide is associated with systemic metabolic health
Sopova, K., Delialis, D., Aivalioti, E., Georgiopoulos, G. A., Athanasopoulos, S., Zervas, G., Konstantaki, C., Sachse, M., Sigl, M., Duerschmied, D., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70171 · Cited by 2
Nurmakova, K., Gomes, G.-N. W., & Levine, Z. A. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113494 · Cited by 2
Zhao, J., Ma, B., & Nussinov, R. (2016) · Israel Journal of Chemistry · doi:10.1002/ijch.201600093 · Cited by 2
Neuroprotective Effects of Extra‐Virgin Olive Oil and its Components in Alzheimer's Disease
Abuznait, A. H., Qosa, H., Mohamed, L. A., Batarseh, Y. S., & Kaddoumi, A. (2017) · Wiley eBooks · doi:10.1002/9781119155195.ch14 · Cited by 2
Binding of ApoE Isoforms to Aβ Peptides and Effects on Their Fibrillization
Friedemann, M., Noormägi, A., Jarvet, J., Gräslund, A., Wärmländer, S. K. T. S., Tõugu, V., & Palumaa, P. (2026) · ACS Omega · doi:10.1021/acsomega.5c12353 · Cited by 1
Protective mutations associated with APOE in Alzheimer’s disease
Ma, Y., Li, Y., Wu, G., Liu, L., Tian, M., Han, X., Chen, X., Xuan, X., Zheng, T., Gao, X., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03496-5 · Cited by 1
Alzheimer's Disease: Search for Therapeutics
Rzeszotarski, W. J. (2003) · Wiley eBooks · doi:10.1002/0471266949.bmc106 · Cited by 1
Apolipoprotein E: Structural and Functional Interactions with Amyloid β
Stine, W. B., & LaDu, M. J. (2005) · Wiley eBooks · doi:10.1002/9783527619344.ch10 · Cited by 1
Self-citationYeast as a Model for Studying Aβ Aggregation, Toxicity and Clearance
Bharadwaj, P. (2011) · Australasian Journal of Paramedicine · Cited by 1
APOE Impacts Lipid Trafficking in Retinal Pigment Epithelium CellsPreprint
Richards, S. E. V., Demirs, J. T., Jose, S., Fan, L., Xu, Y., Esterberg, R., Huang, C. L., Wilson, C. W., Saint‐Geniez, M., & Liao, S.-M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.30.596647 · Cited by 1
Sabbagh, J. J. (2020) · Digital Scholarship - UNLV (University of Nevada Reno) · doi:10.34917/4478299
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Mutka, A. (2009) · Työväentutkimus Vuosikirja
Mecanismos de daño celular en enfermedades neurodegenerativas
Enríquez, S. S., Mora, A. E. R., López, L. D. S. V., Becerra, B. I. C., Hernández, M. A. D., & Hita, M. E. G. (2007) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Role of the 39-kDa receptor-associated protein (RAP) in Alzheimer's disease
Hoang, T. (2012) · UTAS Research Repository · doi:10.25959/23206328
Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk
Cholesterol Disturbances in Inherited Neurodegenerative Diseases
Mutka, A. (2009)
Apolipoprotein E and Mitochondria-associated Endoplasmic Reticulum Dysfunction
Tambini, M. D. (2016)
Adipokines and Alzheimer's Disease
Sortino, M. A., Merlo, S., & Spampinato, S. F. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733434-00130
Kerr, M. E., DeKosky, S. T., Kay, A., & Marion, D. W. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1721-4_15
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Albrecht, M. A., & Foster, J. K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3777-6_7
Analysis of liver X receptor target gene expression across species
Noto, P. B., & Bentz, J. E. (2013) · iDEA - Drexel University Institutional Repository · doi:10.17918/etd-4198
Dorey, E. (2012) · uO Research (University of Ottawa) · doi:10.20381/ruor-6258
The Proteolysis of Apolipoprotein E in Alzheimer's Disease
Love, J. E. (2016) · ScholarWorks (Boise State University)
Apolipoprotein E phenotypes and B-amyloid (1-40) levels in demented patients in Greece
Hatzifilippou, E., Banaki, T., Baloyannis, J., Koutsouraki, E., Balogiannis, S., & Kosta, V. (2008)
Pathogenesis of Alzheimer Disease: Metabolic Factors
(2004) · Springer eBooks · doi:10.1007/0-306-48529-x_15
Metabolism of Aβ: Catabolic and glymphatic systems
Saido, T. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28979-8.00008-5
Human genetics: Establishment of cause-and-effect relationships
Saido, T. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28979-8.00013-9
ApoE and Brain Synaptic Dynamics
Huang, Z. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_68-1
Johnson, N. R., Wang, A. C.-J., Coughlan, C. M., Sillau, S., Lucero, E., Viltz, L., Markham, N. E., Allen, C., Dhanasekaran, A. R., Chial, H. J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20193570
Meuret, C. J., Hu, Y., Smadi, S., Bantugan, M. A., Xian, H., Martinez, A. E., Krauss, R. M., Ma, Q. L., Nedelkov, D., & Yassine, H. N. (2024) · Figshare · doi:10.6084/m9.figshare.26591264
Johnson, N. R., Wang, A. C.-J., Coughlan, C. M., Sillau, S., Lucero, E., Viltz, L., Markham, N. E., Allen, C., Dhanasekaran, A. R., Chial, H. J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20193564
Johnson, N. R., Wang, A. C.-J., Coughlan, C. M., Sillau, S., Lucero, E., Viltz, L., Markham, N. E., Allen, C., Dhanasekaran, A. R., Chial, H. J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20193558
Donovan, K. W., Stefan, E., Bajrami, B., Bennion, M., Huff, S., Mustafa, D. N., Su, M.-J., Dragan, S., Sciabola, S., Chou, Y.-Y., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2025.12.005
Konings, S. C., Nyberg, E., Martinsson, I., Thakore, R., Gouras, G. K., & Klementieva, O. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.10.697647
Hanbouch, L. (2017) · theses.fr (ABES) · doi:10.70675/c4d2c894zf69dz4ae4z9ab1zf4135d0efa12
Chang, A., Kim, M., Glittenberg, M., Qu, W., Li, D., & Li, L. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71568
Apolipoprotein E (ApoE): Structural insights, functionality, and genetic variability
Viswalingam, V., Kumar, D., Tewari, S., & Ganeshpurkar, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40563-1.00001-6
The role of microglia glucose metabolism reprogramming in Alzheimer's disease treatment
Cao, Q., Shen, M., Liu, Y., Li, C., Liu, L., Zhou, J., Yue, R., Niu, D., Ren, Y., Pan, L., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261478594
Cole (2000) · doi:10.1002/1097-0029(20000815)50:4
Self-citation
Metadata
- Authors
- TOKUDA, T., CALERO, M., MATSUBARA, E., VIDAL, R., KUMAR, A., PERMANNE, B., ZLOKOVIC, B., SMITH, J. D., LADU, M. J., ROSTAGNO, A., FRANGIONE, B., & GHISO, J.
- Affiliations
- New York University (US)
- Gunma University (JP)
- Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, U.S.A.
- Department of Neurological Surgery, USC School of Medicine, Los Angeles, CA 90033, U.S.A.
- Rockefeller University (US)
- ENH Research Institute, Evanston, IL 60201, U.S.A.
- Corresponding author
- TOKUDA, Takahiko
- CALERO, Miguel
- KUMAR, Asok
- PERMANNE, Bruno
- ROSTAGNO, Agueda
- FRANGIONE, Blas
- GHISO, Jorge
- ORCID
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2000-05-23
- Volume
- 348
- Issue
- 2
- Pages
- 359-365
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- PMC
- PMC1221074
- OpenAlex
- W2131975162
- Cited by
- 272
- References
- 47
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 12 · 2023: 6 · 2022: 14 · 2021: 10 · 2020: 15 · 2019: 14 · 2018: 6 · 2017: 13 · 2016: 12 · 2015: 10 · 2014: 20 · 2013: 15 · 2012: 14
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Biochemical Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (P01AG010491, AG10491, AG05891)
- National Institute of Neurological Disorders and Stroke (NS 38777, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE3, APOE ε4, Alzheimer's disease, amyloid-beta, lipid modification, delipidation, high-density lipoprotein, amyloid clearance
- MeSH terms
- Animals, Apolipoproteins E, Cell Line, Humans, Kidney, Kinetics, Macrophages, Transfection, Amyloid beta-Peptides, Spodoptera, Protein Isoforms, Mice, Apolipoprotein E3, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
